Problems in the treatment of hepatitis C with interferon

Intervirology

Volumn 42, Issue 2-3, 1999, Pages 166-172

  Iino, Shiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALT normalization; HCV genotype; HCV RNA level; HCV RNA negativity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE COURSE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW;

ALANINE TRANSAMINASE; GENOTYPE; HEPATITIS C; HUMANS; INTERFERONS; PROGNOSIS; RNA, VIRAL;

EID: 0032876783     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024976     Document Type: Review

References (38)

1. Nishioka K: Hepatitis C virus infection in Japan. Gastroenterol Jpn 1991;26(suppl 3):152-155.
2. Osella AR, Misciagna G, Leone A, et al: Epidemiology of hepatitis C virus infection in an area of southern Italy. J Hepatol 1997;27:30-35.
3. Kiyosawa K, Tanaka E, Sodeyama T, et al: Natural history of hepatitis C. Intervirology 1994; 37:101-107.
4. Ho MS, Hsu CP, Yuh Y, et al: High rate of hepatitis C virus infection in an isolated community: Persistent hyperendemicity or period-related phenomena? J Med Virol 1997;52:370-376.
5. Hoofnagle JH, Mullen KD, Jones DB, et al: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 1986;315: 1575-1578.
6. Choo QL, Kuo G, Weiner AJ, et al: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
7. Weiner AJ, Kuo G, Bradle DW. et al: Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990;35:1-3.
8. Okamoto H, Okada S, Sugiyama Y, et al: The 5'-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990;60:167-177.
9. Poynard T, Bedossa P, Opolon P, et al: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349: 825-832.
10. Mathurin P, Moussalli J, Cadranel JF, et al: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27: 868-872.
11. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
12. Bisceglie AMD, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
13. Iino S, Hino K, Kuroki T, et al: Treatment of chronic hepatitis C with high-dose interferon α-2b: A multicenter study. Dig Dis Sci 1993;38: 612-618.
14. Fujisawa K, Tandon BN: Therapeutic approach to the chronic active liver disease: Summary of a satellite symposium; in Nishioka K, Suzuki H, Misiro S, Oda T (eds): Viral Hepatitis and Liver Disease. Tokyo, Springer, 1994, pp 662-665.
15. Arima T, Nagashima H, Shimomura H, et al: Treatment of chronic non-A, non-B hepatitis with human beta-interferon: in Zuckerman AJ (ed): Viral Hepatitis and Liver Disease. New York, Liss, 1988, pp 898-901.
16. Fujioka S, Hino K, Fukuhara A, et al: Treatment of chronic non-A, non-B hepatitis: Comparative study of dosage of human interferon-β. Acta Hepatol Jpn 1989;30:516-524.
17. Iino S, Hino K, Yasuda K: Current state of interferon therapy for chronic hepatitis C. Intervirology 1994;37:87-100.
18. Iino S: Interferon therapy in hepatitis C-refractory hepatitis: Report of the research subgroup of treatment of chronic hepatitis. Gastroenterol Jpn 1993;28(suppl 4):139-142.
19. Iino S: High-dose interferon treatment in chronic hepatitis C. Gut 1993;(suppl):114-118.
20. Zeuzem S, Schmidt JM, Lee JH, et al: Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23: 366-371.
21. Yasui K, Okanoue T, Murakami Y, et al: Dynamics of hepatitis C viremia following interferon-α administration. J Infect Dis 1998;177: 1475-1479.
22. Zaaijer HL, Cuypers HTM, Reesink HW, et al: Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341:722-724.
23. Albahalejo J, Alonso R, Antinozzi R, et al: Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998;36:862-865.
24. Halfon P, Bourliere M, Halimi G, et al: Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: Branched DNA and amplicor monitor. J Clin Microbiol 1998;36:2073-2075.
25. Reichard O, Norkrans G, Frydén A, et al: Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
26. Craxi A, Almasio P, Schalm S (on behalf of EUROHEP): Evaluation of efficacy of antiviral therapy for chronic hepatitis C: A EUROHEP consensus report on response criteria. J Viral Hepat 1996;3:273-276.
27. Enomoto N, Sakuma I, Asahina Y, et al: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224-230.
28. Hino K, Okuda M, Konishi T, et al: Serial assay of hepatitis C virus RNA in serum for prediction response to interferon-α therapy. Dig Dis Sci 1995;40:14-20.
29. Schvarez R, Yun ZB, Sönnerborg A, et al: Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995: 46:43-47.
30. Brillanti S, Garson J, Foli M, et al: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
31. Lai MY, Kao JH, Yang PM, et al: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
32. Poynard T, Marcellin P, Lee SS, et al: Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
33. McHutchinson JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
34. Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
35. Bisceglie AMD, Shindo M, Fang TL, et al: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-654.
36. Iino S: Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan. Antiviral Ther 1998;3(suppl 3):143-146.
37. Degos F, Daurat V, Chevret S, et al: Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicentre randomised trial. J Hepatol 1998;29:224-232.
38. Arase Y, Ikeda K, Murashima N, et al: The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-1500.